HIV New Product Introduction Guide: A framework for supporting new product introduction in national health systems

Clinton Health Access Initiative

Over the past two decades, the landscape of medications used to treat HIV has evolved rapidly. Treatment options have improved dramatically with the development and availability of more efficacious, safer, and more tolerable antiretrovirals (ARVs). These options allow national treatment programs to better serve the needs of their patients, support significant treatment scale-up, reduce costs, and achieve public health goals. Use of the most optimal regimens and products offers many benefits to national HIV programs and people living with HIV (PLHIV).

Accelerating the availability of new, optimal ARVs and expanding treatment coverage are major priorities for patients and governments in low-and middle-income countries (LMICs). Facilitating rapid access to these products will reduce patient morbidity and mortality while at the same time enhancing the long-term viability of public health programs in reaching the 90-90-90 targets set by the Joint United Nations Programme on HIV/AIDS (UNAIDS).The process of adopting new ARV products requires significant strategic planning and coordination across national and international stakeholders.

The HIV New Product Introduction Guide outlines key considerations for introducing new ARV products. This guide provides a framework for ministries of health (MoHs) and partners to guide the product adoption, phase-in planning, and implementation process. The framework is not intended to be a “one size fits all” approach, but should provide approaches and tools that can be tailored to meet local needs and context. While this framework focuses on ARVs, it can also be applied to other health commodities. With the World Health Organization’s (WHO) recent inclusion of dolutegravir (DTG) and lower-dose efavirenz (TLE400) as alternate first-line regimens, and availability of tenofovir disoproxil fumurate/lamivudine/dolutegravir (TLD) as a fixed-dose combination (FDC), countries are moving towards large scale shifts in first-line products. Further, several optimal pediatric products are being rolled out across LMICs, with additional new products in the development pipeline for a small treatment population. Development, implementation and monitoring of detailed, systematic product introduction strategies is critical to ensuring smooth product transitions. The approaches and tools in this guide and the accompanying HIV New Product Introduction Toolkit are designed to help MoHs to direct and manage the transition process.

June 11, 2018
Year of publication
2017
Resource types
Guidelines and Policies, Programmatic guidance
Tags
HIV medication, antiretroviral therapy (ART), pediatric ART, treatment options, antiretroviral drugs, ARVs, public health programs, national health systems, new product introduction

Similar Resources

Timely access to antiretroviral treatment (ART) is vital to ensuring safe motherhood and reducing vertical transmission. Treatment guidance and programming has changed dramatically in recent years.

In late 2015, the Linkages Across the Continuum of HIV Services for Key Populations (LINKAGES) project established a global acceleration initiative to fast-track and strengthen delivery of a comprehensive package of health services for key populations (KPs) at scale. In this context, “…

Malawi, like other countries with a generalized HIV epidemic, is striving to reach the ambitious targets set by UNAIDS known as the three 90's for testing, provision of antiretroviral therapy and viral suppression.

The purpose of this guide is to provide a resource for clinicians on the ground who manage HIV and TB clients on a daily basis.

In all countries where there is an HIV epidemic, certain subgroups of the population are at greater risk of HIV than others. These “key” populations include female sex workers (FSWs), men who have sex with men (MSM), transgender people, and people who inject drugs.

To understand the uptake of HIV services by adolescent women, the authors conducted a retrospective analysis of patient-level data (2011–2013) on services for antenatal care (ANC) and prevention of mother-to-child transmission (PMTCT) in 36 facilities in 5 districts in Zimbabwe.

Remarkable progress is being made on HIV treatment. Ahead of World AIDS Day, UNAIDS has launched a new report showing that access to treatment has risen significantly. In 2000, just 685 000 people living with HIV had access to antiretroviral therapy.

Antiretroviral therapy (ART) that enables suppression of HIV replication has been successfully rolled out at large scale to HIV-positive patients in low-income and middle-income countries.

The Southern African HIV Clinicians Society’s biannual conference, held in Johannesburg, South Africa, from 24-27 October 2018, focused on clinical content for HIV and TB health care workers in the region and featured a wide range of topics…

These guidelines are intended as an update to those published in the Southern African Journal of HIV Medicine in 2014 and the update on when to initiate antiretroviral therapy in 2015.